Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.77 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514366 | 1.00 | FAAH (0.77) | FAAHNAAAMGLLALDH1A1MAPT | |
| SCHEMBL4283094 | 0.89 | FAAH (0.72) | FAAHNAAAALDH1A1RAD52NPSR1 | |
| SCHEMBL7934446 | 0.89 | FAAH (0.72) | FAAHNAAAALDH1A1RAD52NPSR1 | |
| SCHEMBL6120710 | 0.89 | FAAH (0.72) | FAAHNAAAALDH1A1RAD52NPSR1 | |
| SCHEMBL2431478 | 0.89 | FAAH (0.72) | FAAHNAAAALDH1A1RAD52NPSR1 | |
| SCHEMBL6783832 | 0.89 | FAAH (0.72) | FAAHNAAAALDH1A1RAD52NPSR1 | |
| SCHEMBL1037235 | 0.89 | FAAH (0.72) | FAAHNAAAALDH1A1RAD52NPSR1 | |
| SCHEMBL1037246 | 0.89 | FAAH (0.72) | FAAHNAAAALDH1A1RAD52NPSR1 | |
| SCHEMBL7453244 | 0.89 | FAAH (0.72) | FAAHNAAAALDH1A1RAD52NPSR1 | |
| SCHEMBL10687440 | 0.89 | FAAH (0.72) | FAAHNAAAALDH1A1RAD52NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598471-B1 | ESTERS OF O-SUBSTITUTED HYDROXY CARBOXYLIC ACIDS AND PREPARATIONS THEREOF | EASTMAN CHEM CO (US) | 2020-11-25 | — | — | EP | disclosed |
| US-9532938-B2 | Esters of O-substituted hydroxy carboxylic acids and preparations thereof | EASTMAN CHEMICAL COMPANY (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150025247-A1 | ESTERS OF O-SUBSTITUTED HYDROXY CARBOXYLIC ACIDS AND PREPARATIONS THEREOF | EASTMAN CHEM CO (US) | 2015-01-22 | — | — | US | disclosed |
| US-8846723-B2 | Esters of O-substituted hydroxy carboxylic acids and preparations thereof | EASTMAN CHEMICAL COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2598471-A1 | ESTERS OF O-SUBSTITUTED HYDROXY CARBOXYLIC ACIDS AND PREPARATIONS THEREOF | Eastman Chemical Company (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015790-A1 | ESTERS OF O-SUBSTITUTED HYDROXY CARBOXYLIC ACIDS AND PREPARATIONS THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20120029198-A1 | ESTERS OF O-SUBSTITUTED HYDROXY CARBOXYLIC ACIDS AND PREPARATIONS THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20020025920-A1 | Novel lipid complexes for transferring at least one therapeutically active substance, in particular a polynucleotide, into a target cell, and use in gene therapy | BISCHOFF RAINER (SE) | 2002-02-28 | — | — | US | disclosed |
| US-6291423-B1 | Lipid complexes for transferring at least a therapeutically active substance, in particular a polynucleotide into a target cell and use in gene therapy | TRANSGENE S.A. (FR) | 2001-09-18 | — | — | US | disclosed |
| US-3970678-A | Organotin mercaptide process | CINCINNATI MILACRON CHEMICALS, INC. (US) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025247-A1 | ESTERS OF O-SUBSTITUTED HYDROXY CARBOXYLIC ACIDS AND PREPARATIONS THEREOF | HCAR2, OXER1, FASN | FAAH 248/4885NAAA 1003/4885MGLL 1292/4885 |
| US-20120029198-A1 | ESTERS OF O-SUBSTITUTED HYDROXY CARBOXYLIC ACIDS AND PREPARATIONS THEREOF | HCAR2, OXER1, FASN | FAAH 248/4885NAAA 1003/4885MGLL 1292/4885 |
| US-20020025920-A1 | Novel lipid complexes for transferring at least one therapeutically active substance, in particular a polynucleotide, into a target cell, and use in gene therapy | PCYT1A, PLTP, PITPNB | FAAH 2026/4885NAAA 1669/4885MGLL 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.